These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Verschueren KM, Creutzberg CL, Schalij-Delfos NE, Ketelaars M, Klijsen FL, Haeseker BI, Ligtenberg SM, Keunen JE, Marijnen CA. Radiother Oncol; 2010 Jun; 95(3):332-8. PubMed ID: 20416963 [Abstract] [Full Text] [Related]
6. Ruthenium-106 plaque radiotherapy alone or in combination with transpupillary thermotherapy in the management of choroidal melanoma. Gündüz K, Kurt RA, Akmeşe HE, Köse K, Uçakhan-Gündüz O. Jpn J Ophthalmol; 2010 Jul; 54(4):338-43. PubMed ID: 20700803 [Abstract] [Full Text] [Related]
9. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Filì M, Trocme E, Bergman L, See TRO, André H, Bartuma K, Girnita L, All-Eriksson C, Seregard S, Stålhammar G. Br J Ophthalmol; 2020 Jan; 104(1):26-32. PubMed ID: 30910871 [Abstract] [Full Text] [Related]
17. [Risk factors for the recurrence of choroidal melanoma after the Ru-106 brachytherapy]. Bogdali A, Romanowska-Dixon B. Klin Oczna; 2015 Apr; 117(3):169-72. PubMed ID: 26999940 [Abstract] [Full Text] [Related]